The Abbreviated Review pathway has been developed by the Taiwan Food and Drug Administration of Taiwan (Chinese Taipei).

When relevant, the agency relies on prior decisions from EU-EMA Japan United States

Abbreviated Review: 180 days. Submission → filing meeting (~60 days) → review meeting (~100 days) → notification for completion of review (~130 days) → approval/non-approval by TFDA (~180 days)